Acta Haematologica最新文献_第8页

[Momelotinib bei Myelofibrose und Anämie]. [莫迈罗替尼治疗骨髓纤维化和贫血]。

IF 1.7 4区医学

Acta Haematologica Pub Date : 2024-01-01 Epub Date: 2024-03-11 DOI: 10.1159/000538289

引用次数: 0

Immunotherapy for Acute Myeloid Leukemia: Current Trends, Challenges, and Strategies. 急性髓性白血病的免疫疗法：当前趋势、挑战和策略》。

IF 1.7 4区医学

Acta Haematologica Pub Date : 2024-01-01 Epub Date: 2023-09-06 DOI: 10.1159/000533990

Evan C Chen, Jacqueline S Garcia

引用次数: 0

Cellular Therapy in Chronic Lymphocytic Leukemia: Have We Advanced in the Last Decade? 慢性淋巴细胞白血病的细胞治疗：我们在过去十年中取得了进展吗？

IF 1.7 4区医学

Acta Haematologica Pub Date : 2024-01-01 Epub Date: 2023-10-09 DOI: 10.1159/000534341

Ofrat Beyar Katz, Dana Yehudai-Ofir, Tsila Zuckerman

{"title":"Cellular Therapy in Chronic Lymphocytic Leukemia: Have We Advanced in the Last Decade?","authors":"Ofrat Beyar Katz, Dana Yehudai-Ofir, Tsila Zuckerman","doi":"10.1159/000534341","DOIUrl":"10.1159/000534341","url":null,"abstract":"Background: Chronic lymphocytic leukemia (CLL) is a heterogeneous B-cell malignancy, affecting mainly older adults. Despite the recent introduction of multiple targeted agents, CLL remains an incurable disease. Cellular therapy is a promptly evolving area that has developed over the last decades from such standard of care as hematopoietic cell transplantation (HCT) to the novel treatment modalities employing genetically engineered immune cells.Summary: Tailoring the proper treatment for each patient is warranted and should take into account the disease biology, patient characteristics, and the available treatment modalities. Nowadays, the most broadly applied cellular therapies for CLL management are HCT and chimeric antigen receptor-T (CAR-T) cells. However, CAR-T cell therapy is currently not yet approved in CLL, and the appropriate sequencing for the administration of these agents remains to be clarified.Key messages: The current review will discuss various available cellular treatment options, their advances and limitations, as well as the optimal timing for the employment of such therapies in CLL patients.","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"99-112"},"PeriodicalIF":1.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41181753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Addendum to the German Consensus Recommendations on Ponatinib in the Treatment of Chronic Myeloid Leukemia. 关于波纳替尼治疗慢性粒细胞白血病的德国共识建议附录。

IF 1.7 4区医学

Acta Haematologica Pub Date : 2024-01-01 Epub Date: 2023-10-17 DOI: 10.1159/000533666

Susanne Saussele, Paul La Rosée, Alexander Kiani, Wilhelm Haverkamp, Kathleen Jentsch-Ullrich, Frank Stegelmann, Christina Rieger, Cornelius F Waller, Georg-Nikolaus Franke, Christian Junghanss, Rudolf Kirchmair, Markus Theurl, Philipp le Coutre

{"title":"Addendum to the German Consensus Recommendations on Ponatinib in the Treatment of Chronic Myeloid Leukemia.","authors":"Susanne Saussele, Paul La Rosée, Alexander Kiani, Wilhelm Haverkamp, Kathleen Jentsch-Ullrich, Frank Stegelmann, Christina Rieger, Cornelius F Waller, Georg-Nikolaus Franke, Christian Junghanss, Rudolf Kirchmair, Markus Theurl, Philipp le Coutre","doi":"10.1159/000533666","DOIUrl":"10.1159/000533666","url":null,"abstract":"Background: Based on the new data from the primary analysis of the OPTIC (Optimizing Ponatinib Treatment in CP-CML) trial on dose optimization of ponatinib in patients with chronic phase (CP)-CML, the German consensus paper on ponatinib published in 2020 (Saussele S et al., Acta Haematol. 2020) has been updated in this addendum.Summary: Focus is on the update of efficacy and safety of ponatinib, reflecting the new data set, as well as the update of the benefit-risk assessment and recommendations for ponatinib starting dose in CP-CML - provided that the decision to use ponatinib has already been made. Furthermore, based on OPTIC and additional empirical data, the expert panel collaborated to develop a decision tree for ponatinib dosing, specifically for intolerant and resistant patients. The recommendations on cardiovascular management have also been updated based on the most recent 2021 guidelines of the European Society of Cardiology (ESC) on cardiovascular disease prevention in clinical practice.Key messages: The OPTIC data confirm the high efficacy of ponatinib in patients with CP-CML and provide the basis for individualized dose adjustment during the course of treatment.","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"344-351"},"PeriodicalIF":1.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11152025/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41231535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lenalidomide Treatment of Isolated Central Nervous System Relapse in Acute Lymphoblastic Leukemia after Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T-Cell Therapy. 来那度胺治疗造血干细胞移植和 CAR-T 细胞疗法后急性淋巴细胞白血病孤立性中枢神经系统复发。

IF 1.7 4区医学

Acta Haematologica Pub Date : 2024-01-01 Epub Date: 2024-02-15 DOI: 10.1159/000537719

Qing Zhang, Yi Dong, Zhimin Zhai, Lili Tao, Qianshan Tao

{"title":"Lenalidomide Treatment of Isolated Central Nervous System Relapse in Acute Lymphoblastic Leukemia after Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T-Cell Therapy.","authors":"Qing Zhang, Yi Dong, Zhimin Zhai, Lili Tao, Qianshan Tao","doi":"10.1159/000537719","DOIUrl":"10.1159/000537719","url":null,"abstract":"Introduction: Hematopoietic stem cell transplantation (HSCT) and chimeric antigen receptor T (CAR-T) cell are effective treatments for acute lymphoblastic leukemia (ALL). Various forms of intra- and extramedullary relapses have been reported after HSCT and CAR-T-cell therapy for ALL; however, no reports have investigated isolated central nervous system (CNS) relapse after HSCT and CAR-T-cell therapy. Hence, no clinical treatment has been established for such rare patients.Case presentation: An 18-year-old male patient with B-cell ALL suffered from isolated CNS relapse after HSCT and CAR-T-cell therapy. Conventional systemic intravenous and intrathecal chemotherapies were ineffective and intolerable. A unique immunosuppressive microenvironment of decreasing NK cell percentage and increasing IL-8 concentration and CAR-T-cell exhaustion had been illustrated in the cerebrospinal fluid. Finally, the patient received immunomodulatory therapy with lenalidomide and obtained complete remission.Conclusion: Lenalidomide might be a therapeutic strategy for isolated CNS relapse after HSCT and CAR-T-cell therapy.","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"592-597"},"PeriodicalIF":1.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139740144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Oncogenic MTOR Signaling Axis Compensates BTK Inhibition in a Chronic Lymphocytic Leukemia Patient with Richter Transformation: A Case Report and Review of the Literature. 一名里克特转化型慢性淋巴细胞白血病患者的致癌 MTOR 信号轴补偿了 BTK 抑制：病例报告与文献综述。

IF 1.7 4区医学

Acta Haematologica Pub Date : 2024-01-01 Epub Date: 2024-02-24 DOI: 10.1159/000537791

Thomas Parigger, Stephan Drothler, Christian Scherhäufl, Franz Josef Gassner, Maria Schubert, Markus Steiner, Jan Philip Höpner, Alexandra Hödlmoser, Lena Schultheis, Aryunni Abu Bakar, Daniel Neureiter, Lisa Pleyer, Alexander Egle, Richard Greil, Roland Geisberger, Nadja Zaborsky

{"title":"Oncogenic MTOR Signaling Axis Compensates BTK Inhibition in a Chronic Lymphocytic Leukemia Patient with Richter Transformation: A Case Report and Review of the Literature.","authors":"Thomas Parigger, Stephan Drothler, Christian Scherhäufl, Franz Josef Gassner, Maria Schubert, Markus Steiner, Jan Philip Höpner, Alexandra Hödlmoser, Lena Schultheis, Aryunni Abu Bakar, Daniel Neureiter, Lisa Pleyer, Alexander Egle, Richard Greil, Roland Geisberger, Nadja Zaborsky","doi":"10.1159/000537791","DOIUrl":"10.1159/000537791","url":null,"abstract":"Introduction: Targeting the B-cell receptor pathway via ibrutinib, a specific inhibitor of Bruton's tyrosine kinase, has shown marked clinical efficacy in treatment of patients with chronic lymphocytic leukemia (CLL), thus becoming a preferred first line option independent of risk factors. However, acquired resistance to ibrutinib poses a major clinical problem and requires the development of novel treatment combinations to increase efficacy and counteract resistance development and clinical relapse rates.Case presentation: In this study, we performed exome and transcriptome analyses of an ibrutinib resistant CLL patient in order to investigate genes and expression patterns associated with ibrutinib resistance. Here, we provide evidence that ibrutinib resistance can be attributed to aberrant mammalian target of rapamycin (MTOR) signaling.Conclusion: Thus, our study proposes that combined use of MTOR inhibitors with ibrutinib could be a possible option to overcome therapy resistance in ibrutinib treated patients.","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"604-611"},"PeriodicalIF":1.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11441378/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139970590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

In Memoriam: Isaac Ben-Bassat (1937-2023) A Lifelong Legacy in Hematology. 纪念:艾萨克·本·巴萨特(1937-2023)血液学的终身遗产。

IF 2.4 4区医学

Acta Haematologica Pub Date : 2024-01-01 Epub Date: 2023-11-24 DOI: 10.1159/000535013

Pia Raanani

引用次数: 0

Long-Term Clinical Outcomes of Optimizing Combination Therapy for Primary Pulmonary Mucosa-Associated Lymphoid Tissue Lymphoma: A Retrospective Study. 优化联合治疗原发性肺粘膜相关淋巴组织淋巴瘤的长期临床结果:一项回顾性研究

IF 1.7 4区医学

Acta Haematologica Pub Date : 2024-01-01 Epub Date: 2023-11-24 DOI: 10.1159/000535228

Gi-June Min, Chin Kook Rhee, Tong Yoon Kim, Young-Woo Jeon, Joo Hyun O, Byung-Ock Choi, Gyeongsin Park, Seok-Goo Cho

{"title":"Long-Term Clinical Outcomes of Optimizing Combination Therapy for Primary Pulmonary Mucosa-Associated Lymphoid Tissue Lymphoma: A Retrospective Study.","authors":"Gi-June Min, Chin Kook Rhee, Tong Yoon Kim, Young-Woo Jeon, Joo Hyun O, Byung-Ock Choi, Gyeongsin Park, Seok-Goo Cho","doi":"10.1159/000535228","DOIUrl":"10.1159/000535228","url":null,"abstract":"Introduction: Pulmonary mucosa-associated lymphoid tissue (MALT) lymphoma progresses with advancing disease stage. However, no standard treatment approach has been established. This single-center retrospective study evaluated clinical and radiological characteristics, treatment modalities, and long-term prognosis of pulmonary MALT lymphoma.Methods: The study included 42 patients diagnosed with pulmonary MALT lymphoma between October 2004 and July 2019. Primary therapeutic modalities were determined using modified Ann Arbor staging. Therapeutic response was evaluated via computed tomography and laboratory analyses every 6 months for 5 years. Radiological findings were categorized based on the Lugano classification as complete response (CR), partial response, stable disease (SD), or progressive disease.Results: Initial treatment included observation (n = 2), surgical resection (n = 6), or systemic chemotherapy (n = 34). Patients treated surgically had localized disease and achieved initial and long-term CR. Of the 34 patients who underwent chemotherapy, 30 achieved CR, 2 achieved SD, and 2 died. Overall and progression-free survival (PFS) rates were 93.9% and 54.3%, respectively. Multivariate analysis indicated that PFS was lower in patients with modified Ann Arbor stage III-IV lymphoma and those who did not achieve CR.Conclusions: Optimized treatment based on anatomical location, pulmonary function, and disease stage can improve long-term survival in patients with pulmonary MALT lymphoma.","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"413-426"},"PeriodicalIF":1.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11296562/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138440093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Complete Response to Donor Lymphocyte Infusion for Primary Hemophagocytic Lymphohistiocytosis Relapse after Allogeneic Hematopoietic Cell Transplantation. 供体淋巴细胞输注对异基因造血细胞移植后原发性噬血细胞淋巴组织细胞病复发的完全缓解。

IF 1.7 4区医学

Acta Haematologica Pub Date : 2024-01-01 Epub Date: 2023-11-23 DOI: 10.1159/000535449

Rutvij A Khanolkar, Nathan Kuehne, Jan Storek

引用次数: 0

A Rare Clinical Case of Secondary Central Nervous System Involvement without Transformation in Hairy Cell Leukemia: A Case Report and Literature Review. 毛细胞白血病继发性中枢神经系统受累无转化1例报告并文献复习。

IF 1.7 4区医学

Acta Haematologica Pub Date : 2024-01-01 Epub Date: 2023-11-10 DOI: 10.1159/000535066

Kenichi Ito, Kunihiko Harada, Yoshihito Uchino, Kazuhiko Hirano, Naohiro Sekiguchi

{"title":"A Rare Clinical Case of Secondary Central Nervous System Involvement without Transformation in Hairy Cell Leukemia: A Case Report and Literature Review.","authors":"Kenichi Ito, Kunihiko Harada, Yoshihito Uchino, Kazuhiko Hirano, Naohiro Sekiguchi","doi":"10.1159/000535066","DOIUrl":"10.1159/000535066","url":null,"abstract":"Introduction: Hairy cell leukemia (HCL) is an indolent B-cell lymphoma characterized by a specific genetic mutation, BRAF V600E, which affects the specific morphology and oncogenesis. For HCL, few reports regarding secondary central nervous system involvement (SCNSI) are available. Herein, we present the case of an 80-year-old woman who had a relapse of HCL with SCNSI.Case presentation: The diagnosis of HCL was made in June 2015 after identifying BRAF V600E proteins by immunohistochemical analysis, and the disease was then controlled for 6 years by employing chemoimmunotherapy. In February 2021, the patient was admitted with neurological symptoms such as dizziness. Magnetic resonance imaging of the brain showed abnormal enhancement in the cerebrum, and cerebrospinal fluid analysis revealed neoplastic cells without transformation into large cells. Thus, the patient was diagnosed as having SCNSI in HCL.Conclusion: We report a case of a rare clinical presentation of SCNSI in HCL with literature review.","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"482-488"},"PeriodicalIF":1.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89716591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0